ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
40.77
0.00%
US Tech 100
20,509.20
-1.83%
S&P 500
6,040.53
-0.50%
US Dollar vs CAD
1.46699
-0.30%
Bitcoin
94,932.96
-2.83%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Europe
  5. EU
  6. Inventiva (IVA)

  7. Inventiva (IVA) News

IVA

Inventiva (IVA)

Inventiva
Date:
Sort by:
 Showing the most relevant articles for your search:EU:IVA
DateTimeSourceHeadlineSymbolCompany
01/29/20253:00PMGlobeNewswire Inc.Inventiva announces the publication of the results from the investigator-initiated proof-of-concept clinical trial evaluating lanifibranor in patients with T2D and MASLD in the Journal of HepatologyEU:IVAInventiva
01/24/20253:00PMGlobeNewswire Inc.Half-Year Review of Inventiva’s Liquidity Contract with Kepler CheuvreuxEU:IVAInventiva
01/22/20253:00PMGlobeNewswire Inc.Results of LEGEND evaluating lanifibranor in combination with empagliflozin in MASH selected for oral presentation at the upcoming EASL SLD Summit 2025EU:IVAInventiva
12/17/20243:00PMGlobeNewswire Inc.Inventiva to present at the 43rd Annual J.P. Morgan Healthcare ConferenceEU:IVAInventiva
12/16/20241:30AMGlobeNewswire Inc.Inventiva secures €21.4 million and completes the first tranche of the previously announced multi-tranche financing of up to €348 millionEU:IVAInventiva
12/12/20243:00PMGlobeNewswire Inc.Results of the votes of the Combined Shareholders’ General Meeting of December 11, 2024EU:IVAInventiva
11/21/20243:00PMGlobeNewswire Inc.Inventiva reports 2024 Third Quarter Financial Information¹EU:IVAInventiva
11/20/20243:00PMGlobeNewswire Inc.Combined General Meeting of December 11, 2024 - Availability of the preparatory documentsEU:IVAInventiva
11/15/20243:00PMGlobeNewswire Inc.Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker sessionEU:IVAInventiva
10/30/20243:00PMGlobeNewswire Inc.Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASHEU:IVAInventiva
10/21/20247:30AMGlobeNewswire Inc.Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024EU:IVAInventiva
10/14/202412:45PMGlobeNewswire Inc.Inventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrantsEU:IVAInventiva
10/14/20241:35AMGlobeNewswire Inc.Inventiva announces Filing of 2024 Half-Year Report – Conditions for Accessing or Consulting the ReportEU:IVAInventiva
10/14/20241:30AMGlobeNewswire Inc.Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH studyEU:IVAInventiva
09/25/20243:00PMGlobeNewswire Inc.Inventiva provides a corporate update and reports its unaudited 2024 first-half financial resultsEU:IVAInventiva
07/31/20243:00PMGlobeNewswire Inc.Inventiva Reports Preliminary 2024 First-Half Financial Information¹EU:IVAInventiva
07/25/20243:00PMGlobeNewswire Inc.Inventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranorEU:IVAInventiva
07/18/20241:30AMGlobeNewswire Inc.Inventiva announces a €20.1 million issuance of royalty certificatesEU:IVAInventiva
07/05/20243:00PMGlobeNewswire Inc.Inventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial position  EU:IVAInventiva
07/05/20243:00PMGlobeNewswire Inc.Inventiva fait le point sur son programme clinique NATiV3 évaluant lanifibranor dans la MASH/NASH et sur sa situation financièrEU:IVAInventiva
07/05/20243:00PMGlobeNewswire Inc.Inventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial position  EU:IVAInventiva
06/21/20243:05PMGlobeNewswire Inc.Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 20 June 2024  EU:IVAInventiva
06/21/20243:05PMGlobeNewswire Inc.DESCRIPTIF DU PROGRAMME DE RACHAT D’ACTIONS AUTORISE PAR L'ASSEMBLEE GENERALE ORDINAIRE DU 20 JUIN 2024EU:IVAInventiva
06/21/20243:05PMGlobeNewswire Inc.Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 20 June 2024  EU:IVAInventiva
06/21/20243:00PMGlobeNewswire Inc.Results of the votes of the Combined Shareholders’ General Meeting of June 20, 2024  EU:IVAInventiva
06/21/20243:00PMGlobeNewswire Inc.Résultats des votes de l’Assemblée Générale Mixte des actionnaires réunies le 20 juin 2024EU:IVAInventiva
06/21/20243:00PMGlobeNewswire Inc.Results of the votes of the Combined Shareholders’ General Meeting of June 20, 2024  EU:IVAInventiva
05/30/20241:30AMGlobeNewswire Inc.Assemblée Générale Mixte du 20 juin 2024 - Modalités de mise à disposition des documents préparatoiresEU:IVAInventiva
05/30/20241:30AMGlobeNewswire Inc.Combined General Meeting of June 20, 2024 - Availability of the preparatory documentsEU:IVAInventiva
05/30/20241:30AMGlobeNewswire Inc.Statement of total voting rights and shares forming the company’s share capital as of May 13, 2024EU:IVAInventiva
 Showing the most relevant articles for your search:EU:IVA

Your Recent History

COIN
XRPUSD
Ripple
USOTC
LQMT
Liquidmetal Technologies (QB)
COIN
BTCUSD
Bitcoin
USOTC
RSPI
RespireRx Pharmaceuticals (CE)
COIN
SHIBUSD
SHIBA INU
NASDAQ
TSLA
Tesla
USOTC
MONI
Moon Equity (PK)
USOTC
BIEL
Bioelectronics (PK)
NASDAQ
COOP
Mr Cooper
NASDAQ
LWLG
Lightwave Logic
NASDAQ
NVDA
NVIDIA
NASDAQ
AVXL
Anavex Life Sciences
USOTC
RDGL
Vivos (QB)
USOTC
NWBO
Northwest Biotherapeutics (QB)
USOTC
IGPK
Intergrated Cannabis Sol... (PK)
NASDAQ
AMRN
Amarin
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads